Cobra Bags New Adenovirus Service Contract

Cobra Biomanufacturing (Cobra) has signed an agreement with a European biotechnology company to provide development services for an Adenovirus-based product.

The contract will focus on the application of Cobra’s proprietary virus purification platform, which is based on scalable chromatographic operations and integrates single use technologies throughout.

Simon Saxby, chief executive of Cobra, said: We are very pleased to have been selected by this company as this underlines Cobra’s extensive experience and expertise in producing virus based products for clinical trials. This agreement also highlights Cobra’s continued commitment to be the CMO of choice for virus production.

Cobra is a contract manufacturer of biopharmaceuticals, dedicated to designing solutions for the production of preclinical and clinical proteins, viruses, DNA and cell products.